Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

被引：163
|
作者：
Tausch, Eugen [1 ]
Close, William [1 ]
Dolnik, Anna [2 ]
Bloehdorn, Johannes [1 ]
Chyla, Brenda [3 ]
Bullinger, Lars [2 ]
Doehner, Hartmut [1 ]
Mertens, Daniel [1 ,4 ]
Stilgenbauer, Stephan [1 ,5 ]
机构：
[1] Ulm Univ, Dept Internal Med 3, Ulm, Germany
[2] Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[3] AbbVie, N Chicago, IL USA
[4] Deutsch Krebsforschungszentrum DKFZ, Cooperat Unit Mech Leukemogenesis, Heidelberg, Germany
[5] Saarland Univ, Sch Med, Dept Hematol Oncol & Rheumatol, Homburg, Germany
来源：
HAEMATOLOGICA | 2019年 / 104卷 / 09期
关键词：
ABT-199;
D O I：
10.3324/haematol.2019.222588
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
    Yalniz, Fevzi F.
    Wierda, William G.
    DRUGS, 2019, 79 (12) : 1287 - 1304
  • [22] Expert Variant Curation Combined with in-Silico analysis for Clinical Interpretation of BCL2 variants in Resistance to BCL2 Inhibitors in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
    Mccoy, Matthew
    Rao, Shruti
    Cosgrove, Shannon
    Madhavan, Subha
    Kulkarni, Shashikant
    Xu, Xinjie
    Kanagal-Shamanna, Rashmi
    BLOOD, 2020, 136
  • [23] NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia
    Fiorcari, Stefania
    Maffei, Rossana
    Atene, Claudio Giacinto
    Martinelli, Silvia
    Potenza, Leonardo
    Luppi, Mario
    Marasca, Roberto
    BLOOD, 2019, 134
  • [24] Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia
    Seymour, John
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 440 - 443
  • [25] Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax
    Lew, Thomas E.
    Anderson, Mary Ann
    Tam, Constantine S.
    Huang, David C. S.
    Juneja, Surender
    Westerman, David A.
    Seymour, John F.
    Roberts, Andrew W.
    BLOOD, 2016, 128 (22)
  • [26] Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
    Jain, Nitin
    Croner, Lisa J.
    Allan, John N.
    Siddiqi, Tanya
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Eckert, Karl
    Cheung, Leo W. K.
    Mukherjee, Anwesha
    Dean, James P.
    Szafer-Glusman, Edith
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2024, 30 (03) : 498 - 505
  • [27] Emergence of IGH::CCND1 rearrangement and mutations in TP53, BTK, and BCL2 associated with therapy resistance in chronic lymphocytic leukemia
    Wei, Qing
    Fang, Hong
    Jing, James M.
    Segura-Rivera, Roman
    Medeiros, L. Jeffrey
    Wang, Wei
    EJHAEM, 2024, 5 (06): : 1265 - 1268
  • [28] NOTCH2 CONTRIBUTES TO VENETOCLAX RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA.
    Fiorcari, S.
    Maffei, R.
    Atene, C. G.
    Martinelli, S.
    Potenza, L.
    Luppi, M.
    Marasca, R.
    HAEMATOLOGICA, 2020, 105 : S28 - S29
  • [29] Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
    Moore, Victoria Del Gaizo
    Brown, Jennifer R.
    Certo, Michael
    Love, Tara M.
    Novina, Carl D.
    Letai, Anthony
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01): : 112 - 121
  • [30] Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA
    Otake, Yoko
    Soundararajan, Sridharan
    Sengupta, Tapas K.
    Kio, Ebenezer A.
    Smith, James C.
    Pineda-Roman, Mauricio
    Stuart, Robert K.
    Spicer, Eleanor K.
    Fernandes, Daniel J.
    BLOOD, 2007, 109 (07) : 3069 - 3075
12345